Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 709-715

  Psyrri, A ^a,d   Kountourakis, P ^a   Yu, Z ^a   Papadimitriou, C ^b   Markakis, S ^b   Camp, R L ^a   Economopoulos, T ^c   Dimopoulos, M A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d YALE CANCER CENTER   (United States)

Author keywords

AQUA; Ovarian cancer; p53

Indexed keywords

CARBOPLATIN; PACLITAXEL; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANIMAL TISSUE; ARTICLE; AUTOMATION; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY;

ADULT; AGED; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; OVARIAN NEOPLASMS; PROGNOSIS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34047147455     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl479     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Niloff JM, Knapp RC, Schaetzl E et al. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol 1984; 64: 703-707.
3. Milner BJ, Allan LA, Eccles DM et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53: 2128-2132.
4. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986; 6: 1379-1385.
5. Prives C, Hall AP. The p53 pathway. J Pathol 1999; 187: 112-126.
6. Kastan MB, Onyekwere O, Sidransky D et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-6311.
7. Greenblatt MS, Bennett WP, Hollstein M et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
8. Hartmann LC, Podratz KC, Keeney GL et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994; 12: 64-69.
9. Baekelandt M, Kristensen GB, Nesland JM et al. Clinical significance of apoptosis-related factors p53, Mdm2, and Bcl-2 in advanced ovarian cancer. J Clin Oncol 1999; 17: 2061-2068.
10. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002; 8: 1323-1327.
11. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publications, No. 48, Geneva: WHO 1979; 16-21.
12. Rimm DL, Camp RL, Charette LA et al. Tissue microarray: A new technology for amplification of tissue resources. Cancer J 2001; 7: 24-31.
13. Weinberger PM, Yu Z, Haffty BG et al. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10: 5684-5691.
14. Bonsing BA, Corver WE, Gorsira MC et al. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry. Cytometry 1997; 28: 11-24.
15. Yu Z, Weinberger PM, Provost E et al. beta-Catenin functions mainly as an adhesion molecule in patients with squamous cell cancer of the head and neck. Clin Cancer Res 2005; 11: 2471-2477.
16. Yu Z, Weinberger PM, Haffty BG et al. Cyclin d1 is a valuable prognostic marker in oropharyngeal squamous cell carcinoma. Clin Cancer Res 2005; 11: 1160-1166.
17. Altman DG, Lausen B, Sauerbrei W et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829-835.
18. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004; 10: 7252-7259.
19. Sheridan E, Silcocks P, Smith J et al. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance. Eur J Cancer 1994; 30A: 1701-1704.
20. Marks JR, Davidoff AM, Kerns BJ et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979-2984.
21. Ferrandina G, Fagotti A, Salerno MG et al. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. Br J Cancer 1999; 81: 733-740.
22. Havrilesky L, Darcy M, Hamdan H et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2003; 21: 3814-3825.
23. Reles A, Wen WH, Schmider A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-2997.
24. Bergh J, Norberg T, Sjogren S et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995; 1: 1029-1034.
25. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995; 55: 5217-5221.
26. Skaug V, Ryberg D, Kure EH et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6: 1031-1037.
27. Niwa K, Itoh M, Murase T et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 70: 1191-1197.
28. Fallows S, Price J, Atkinson RJ et al. P53 mutation does not affect prognosis in ovarian epithelial malignancies. J Pathol 2001; 194: 68-75.
29. Shahin MS, Hughes JH, Sood AK et al. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000; 89: 2006-2017.
30. Sood AK, Sorosk JI, Dolan M et al. Distant metastases in ovarian cancer: association with p53 mutations. Clin Cancer Res 1999; 5: 2485-2490.
31. Rose SL, Robertson AD, Goodheart MJ et al. The impact of p53 protein core domain structural alteration on ovarian cancer survival. Clin Cancer Res 2003; 9: 4139-4144.
32. Hashimoto T, Tokuchi Y, Hayashi M et al. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas. Cancer Res 1999; 59: 5572-5577.